A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma

Joseph J. Maly, Beth A. Christian, Xiaohua Zhu, Lai Wei, Jennifer L. Sexton, Samantha M. Jaglowski, Steven M. Devine, Todd A. Fehniger, Nina Wagner-Johnston, Mitch A. Phelps, Nancy L. Bartlett, Kristie A. Blum

Research output: Contribution to journalArticle

Abstract

Micro-Abstract On the basis of previous studies showing single-agent efficacy with lenalidomide and panobinostat in patients with relapsed or refractory Hodgkin lymphoma (HL), we conducted a phase I/II study to evaluate the safety and efficacy of the combination in this patient population. The recommended phase II dose was 25 mg lenalidomide on days 1 to 21 with 15 mg panobinostat 3 times per week, and an overall response rate of 16.7% in patients was observed, with a durable response in 1 patient with lymphocyte-predominant HL.

Original languageEnglish (US)
Pages (from-to)347-353
Number of pages7
JournalClinical Lymphoma, Myeloma and Leukemia
Volume17
Issue number6
DOIs
StatePublished - Jun 1 2017

Keywords

  • Clinical trial
  • Hodgkin's lymphoma
  • Lenalidomide
  • Panobinostat
  • Relapsed/refractory

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma'. Together they form a unique fingerprint.

  • Cite this

    Maly, J. J., Christian, B. A., Zhu, X., Wei, L., Sexton, J. L., Jaglowski, S. M., Devine, S. M., Fehniger, T. A., Wagner-Johnston, N., Phelps, M. A., Bartlett, N. L., & Blum, K. A. (2017). A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 17(6), 347-353. https://doi.org/10.1016/j.clml.2017.05.008